Finding new genetic causes of atypical hemolytic uremic syndrome
Discovering Novel Genetic Causes and Molecular Mechanisms of Atypical Hemolytic Uremic Syndrome
This study is looking at a rare condition called atypical hemolytic uremic syndrome (aHUS) to find new genetic changes that might cause it, and it’s for patients who want to help us learn more about how these changes affect blood vessel cells, which could lead to better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10677017 on NIH RePORTER |
What this research studies
This research investigates atypical hemolytic uremic syndrome (aHUS), a severe condition often linked to genetic factors. The team aims to identify novel genetic mutations that contribute to aHUS by analyzing a large group of patients using advanced next-generation sequencing techniques. Additionally, they will explore how specific genetic changes affect the function of blood vessel cells, which could lead to new treatment options. The study combines genetic analysis with laboratory models to better understand the disease mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with atypical hemolytic uremic syndrome, particularly those with unexplained cases or a family history of the condition.
Not a fit: Patients with atypical hemolytic uremic syndrome caused solely by Shiga-toxin producing E. coli infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and targeted therapies for patients with atypical hemolytic uremic syndrome.
How similar studies have performed: Previous research has successfully identified genetic mutations related to aHUS, but this study aims to uncover new genetic factors, making it a novel approach.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Attanasio, Massimo — University of Iowa
- Study coordinator: Attanasio, Massimo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.